Vortioxetine represents the most mechanistically elaborate of the newer oral antidepressants. It combines serotonin transporter (SERT) inhibition with direct agonist, partial agonist, and antagonist activity at multiple serotonin receptor subtypes, producing a pharmacological profile that is distinct from selective serotonin reuptake inhibitors (SSRIs) both at the receptor level and in terms of its cognitive effects.
Vortioxetine inhibits SERT with high affinity, blocking reuptake of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft in a manner comparable to conventional SSRIs. However, it simultaneously acts directly at multiple 5-HT receptor subtypes: it is a full agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors, and an antagonist at 5-HT1D, 5-HT3, and 5-HT7 receptors.1 This receptor combination produces effects on serotonergic neurotransmission that differ qualitatively from simple reuptake blockade. The 5-HT1A agonism activates somatodendritic autoreceptors on raphe neurons and postsynaptic 5-HT1A receptors in prefrontal and hippocampal circuits. The 5-HT3 and 5-HT7 antagonism disinhibits the release of norepinephrine (NE), dopamine (DA), acetylcholine (ACh), and histamine in cortical and hippocampal regions by removing inhibitory serotonergic tone from GABAergic interneurons that gate those neurotransmitter systems.2 The net effect is an enhancement of not only serotonergic but also cholinergic, noradrenergic, and dopaminergic neurotransmission in prefrontal and hippocampal circuits, providing a mechanistic basis for the cognitive effects observed in clinical trials.
Vortioxetine has been studied more extensively for cognitive effects than any other antidepressant. The FOCUS trial, a randomized controlled trial in patients with major depressive disorder (MDD) who had responded inadequately to SSRIs or serotonin-norepinephrine reuptake inhibitors (SNRIs), demonstrated that vortioxetine 10 mg and 20 mg produced statistically significant improvements in a composite cognitive battery assessing processing speed, attention, and executive function compared with placebo.3 The cognitive improvements were present even after controlling for changes in depression severity, suggesting that the effect on cognition is at least partially independent of antidepressant response rather than simply a consequence of mood improvement. This finding is clinically relevant because cognitive impairment, including deficits in attention, working memory, and executive function, is a major determinant of functional disability in MDD and frequently persists even when mood symptoms remit with conventional antidepressants.3 Whether the cognitive benefit of vortioxetine translates into better functional outcomes in occupational and social domains than SSRIs remains an active area of investigation.
Vortioxetine is well absorbed orally with a bioavailability of approximately 75%, unaffected by food. It is extensively metabolized by cytochrome P450 (CYP) enzymes, with CYP2D6 as the primary pathway, followed by CYP3A4 and CYP2C9. The primary metabolite, Lu AA34443, is pharmacologically inactive and is eliminated renally.11 The elimination half-life of the parent compound is approximately 66 hours, supporting once-daily dosing. CYP2D6 poor metabolizers achieve plasma concentrations approximately twice those of extensive metabolizers at the same dose; dose reduction to 10 mg once daily is recommended in CYP2D6 poor metabolizers or when potent CYP2D6 inhibitors such as bupropion or fluoxetine are coadministered.11 Conversely, CYP2D6 inducers require dose adjustment upward. The approved dose range is 5 mg to 20 mg once daily, with higher doses associated with greater efficacy in clinical trials in some analyses.
Nausea is the most common adverse effect, occurring in approximately 20% to 30% of patients and showing a clear dose-response relationship; it typically attenuates over the first one to two weeks of treatment and can be mitigated by initiating at 5 mg for one week before escalating. Unlike SSRIs and SNRIs, vortioxetine has a favorable sexual dysfunction profile, with clinical trial data demonstrating rates of sexual dysfunction comparable to placebo on prospective assessment instruments.11 This favorable profile likely reflects the combination of 5-HT3 antagonism and multimodal serotonergic activity, since 5-HT2 receptor activation is believed to be a primary mediator of SSRI-induced sexual dysfunction, and vortioxetine does not produce sustained 5-HT2 activation. Weight gain and sedation are not prominent features of the adverse effect profile. Vortioxetine does not carry a risk of prolonged QTc interval at therapeutic doses, which is an advantage over agents such as citalopram and escitalopram at higher doses.
Vortioxetine is a reasonable choice in patients with MDD in whom cognitive dysfunction is prominent, in patients who have failed an adequate SSRI trial but tolerated it reasonably well, and in patients in whom sexual dysfunction with prior antidepressants was a primary reason for discontinuation. Its higher acquisition cost relative to generic SSRIs is a practical consideration.
Vilazodone was designed around a specific mechanistic rationale: by combining SERT inhibition with partial agonism at the 5-HT1A receptor, it would simultaneously block serotonin reuptake and directly engage the somatodendritic autoreceptors whose desensitization is required before full antidepressant effect is achieved. The hypothesis was that direct 5-HT1A partial agonism would accelerate or enhance autoreceptor desensitization relative to an SSRI acting solely through increased synaptic 5-HT, potentially reducing the lag period or improving efficacy in patients with suboptimal autoreceptor downregulation.4 Whether this pharmacological design advantage translates into clinically meaningful superiority over SSRIs in head-to-head comparison has not been consistently demonstrated in randomized trials, but the mechanistic rationale remains sound and distinguishes vilazodone from conventional SSRIs in its receptor-level activity.
Vilazodone inhibits SERT with high affinity, comparable in potency to sertraline and escitalopram. Its 5-HT1A partial agonism is approximately equivalent in affinity to buspirone at the 5-HT1A receptor, though buspirone lacks SERT inhibitory activity.4 The combination means that vilazodone acts on two distinct sites simultaneously: it increases synaptic 5-HT by blocking its transporter while also directly engaging 5-HT1A receptors, which are located both somatodendritically on raphe neurons (autoreceptors) and postsynaptically on pyramidal neurons in the prefrontal cortex (PFC) and hippocampus. The partial agonist activity at 5-HT1A may exert anxiolytic effects through postsynaptic hippocampal 5-HT1A receptors, which has led to interest in its efficacy in anxiety disorders. Vilazodone has no meaningful affinity for histamine H1, muscarinic acetylcholine, or adrenergic alpha-1 receptors, which predicts a cleaner adverse effect profile than mirtazapine or TCAs in terms of sedation, weight gain, and orthostatic hypotension.
Vilazodone has an oral bioavailability of approximately 72% when taken with food, but only approximately 47% in the fasted state, a difference clinically significant enough that coadministration with food is a prescribing requirement rather than a recommendation.4 The prescribing information explicitly states that patients should take vilazodone with food to ensure adequate drug exposure. The elimination half-life is approximately 25 hours, supporting once-daily dosing. Metabolism is primarily hepatic via CYP3A4, with minor contributions from CYP2C19 and CYP2D6. Strong CYP3A4 inhibitors, including azole antifungals and certain macrolide antibiotics, substantially increase vilazodone exposure and require dose reduction to 20 mg daily. Vilazodone is a moderate inhibitor of CYP3A4 at therapeutic concentrations, which should be considered when coadministering CYP3A4-sensitive substrates. The approved dose range is 10 mg once daily for the first week, titrated to 20 mg once daily for the second week, with a target dose of 40 mg once daily thereafter. The titration schedule is intended to minimize early gastrointestinal adverse effects.
Gastrointestinal effects, particularly diarrhea, nausea, and vomiting, are the most common adverse effects of vilazodone and are the primary reason for early discontinuation in clinical trials.4 The diarrhea associated with vilazodone is more prominent than with most SSRIs and appears to be related to 5-HT1A partial agonism at enteric neurons in addition to SERT inhibition at the gut level. The mandatory food coadministration partially mitigates gastrointestinal effects but does not eliminate them. As with vortioxetine, the sexual dysfunction profile of vilazodone appears more favorable than SSRIs in clinical trial data, which has been attributed to the 5-HT1A partial agonism counteracting the 5-HT2-mediated sexual adverse effects associated with elevated synaptic 5-HT. However, this claimed advantage over SSRIs in sexual function has been questioned because the comparison trials used passive rather than prospective sexual function assessment in many cases. Vilazodone does not produce clinically significant weight gain, sedation, or QTc prolongation at therapeutic doses.
Vilazodone must be taken with food. Bioavailability falls from approximately 72% to 47% in the fasted state, which is a clinically meaningful reduction in drug exposure. Patients who take vilazodone without food may experience inadequate therapeutic effect despite prescription at the correct dose. This is among the more clinically consequential food-drug interactions for any commonly prescribed antidepressant.
Trazodone and nefazodone are classified as serotonin antagonist and reuptake inhibitors (SARIs). Both block SERT and simultaneously antagonize postsynaptic 5-HT2A and 5-HT2C receptors. Despite this shared pharmacological mechanism, their clinical roles and safety profiles differ substantially, with nefazodone's use now largely restricted by an idiosyncratic hepatotoxicity risk that emerged post-marketing.
Trazodone inhibits SERT and blocks 5-HT2A receptors, but its antidepressant potency through SERT inhibition is lower than SSRIs at typical clinical doses. Its most prominent pharmacodynamic property at the doses most commonly prescribed in clinical practice, 25 mg to 150 mg at bedtime, is potent histamine H1 receptor antagonism combined with alpha-1 adrenergic blockade, which produces sedation without the respiratory depression associated with benzodiazepines or the next-day grogginess seen with sedating antihistamines.5 The 5-HT2A antagonism additionally promotes slow-wave sleep. For these reasons, trazodone is one of the most commonly prescribed hypnotics in clinical practice, despite its formal indication being as an antidepressant. Its use as a stand-alone antidepressant at doses sufficient to produce antidepressant effect, typically 300 mg to 600 mg per day, is limited by sedation, orthostatic hypotension, and tolerability concerns at those higher doses. Trazodone is FDA-approved for MDD but is used off-label for insomnia in the majority of prescriptions written.
Priapism is a rare but clinically important adverse effect of trazodone, occurring in approximately 1 in 6000 to 1 in 8000 male patients, mediated by alpha-1 adrenergic blockade in penile vasculature.5 Patients should be warned of this risk at initiation, as delayed treatment of priapism can result in irreversible erectile dysfunction. Orthostatic hypotension, dizziness, and excessive daytime sedation are the most common dose-limiting adverse effects in practice. Trazodone has a negligible effect on cardiac conduction and is generally safe in cardiac patients, which is an advantage over TCAs and some antipsychotics used as augmenting agents. At hypnotic doses, trazodone does not produce physical dependence or tolerance, does not require scheduling, and does not carry the respiratory depression risk of benzodiazepines or the next-morning cognitive impairment risk of longer-acting hypnotics, making it a common choice for insomnia management in patients with MDD and in those with contraindications to other hypnotics.
Nefazodone shares trazodone's core SARI mechanism, with SERT inhibition and potent 5-HT2A antagonism, but has a more favorable sedation and orthostatic hypotension profile than trazodone because it lacks trazodone's prominent alpha-1 adrenergic blocking activity. Nefazodone was studied extensively for its effects on sleep architecture and was shown to maintain or improve REM sleep duration, in contrast to SSRIs and SNRIs, which typically suppress REM sleep. Post-marketing, nefazodone was found to cause severe idiosyncratic hepatotoxicity, including fulminant hepatic failure and fatal cases, at a rate estimated at approximately 1 in 250,000 to 1 in 300,000 patient-years of exposure.6 The mechanism appears to involve the nefazodone metabolite para-hydroxynefazodone inhibiting mitochondrial electron transport chain complex I, generating reactive oxygen species and producing mitochondria-mediated hepatocyte apoptosis. The branded formulation of nefazodone was withdrawn from the market in the United States in 2004 and from most other markets thereafter. Generic nefazodone remains technically available in the United States with a black box warning for hepatotoxicity, but its use is now rare, confined to patients with refractory depression who have failed multiple alternatives and for whom the risk-benefit calculation has been explicitly assessed and documented.
Nefazodone is a potent inhibitor of CYP3A4, producing clinically significant drug interactions with any CYP3A4-metabolized substrate. Coadministration with statins metabolized by CYP3A4, including simvastatin and lovastatin, substantially increases statin exposure and raises the risk of myopathy and rhabdomyolysis. Nefazodone is contraindicated with triazolam and alprazolam, both CYP3A4 substrates, as it markedly increases their plasma concentrations. Concomitant use with pimozide, cisapride, or carbamazepine is also contraindicated.12 These interaction constraints, combined with the hepatotoxicity risk, make nefazodone a pharmacologically complex agent that requires careful drug interaction review before any prescription is considered.
Nefazodone carries a black box warning for life-threatening hepatic failure. Baseline liver function tests should be obtained before initiation and monitored periodically. Any patient developing signs of hepatic dysfunction, including jaundice, right upper quadrant pain, dark urine, or unexplained fatigue, requires immediate discontinuation and hepatic evaluation. Nefazodone should not be initiated in patients with active hepatic disease or significantly elevated baseline transaminases.
Agomelatine is structurally derived from melatonin and acts through a mechanism that is unique among approved antidepressants: it is an agonist at MT1 and MT2 melatonin receptors and simultaneously an antagonist at 5-HT2C receptors.7 It has no significant activity at monoamine transporters, making it the only approved antidepressant with antidepressant efficacy that does not directly inhibit SERT, NET, or the dopamine transporter (DAT). Agomelatine is approved in Europe and Australia but has not received FDA approval in the United States. Understanding its mechanism is clinically valuable because it illustrates a non-monoaminergic pathway to antidepressant action and because agomelatine is occasionally encountered in patients transferring care from systems where it is available.
MT1 and MT2 receptor agonism synchronizes circadian rhythms by reinforcing the endogenous melatonin signal from the suprachiasmatic nucleus (SCN), the master circadian pacemaker. Disruption of circadian rhythm, particularly of the sleep-wake cycle, is a prominent and early feature of MDD; agomelatine's MT1/MT2 agonism directly addresses this circadian component of depressive pathophysiology rather than targeting it secondarily through improved sleep. The 5-HT2C antagonism disinhibits dopaminergic and noradrenergic neurotransmission in the PFC and nucleus accumbens, because tonic 5-HT2C receptor activity on GABAergic interneurons inhibits DA and NE release in those regions; blockade of 5-HT2C removes this inhibitory brake, increasing DA and NE availability in frontal circuits.7 This dual mechanism produces antidepressant and anxiolytic effects through pathways entirely distinct from SERT inhibition. The combination of circadian resynchronization and enhanced PFC dopaminergic and noradrenergic tone provides a mechanistic framework for agomelatine's efficacy in both mood and anxiety symptoms and for its consistently favorable effects on subjective sleep quality reported in clinical trials.
Agomelatine is administered once daily at bedtime, at doses of 25 mg or 50 mg. Its oral bioavailability is low and highly variable, approximately 3% to 5% on average in the general population due to extensive first-pass hepatic metabolism, though some individuals achieve bioavailabilities above 80% due to pharmacokinetic variability. This wide inter-individual variability is clinically relevant: it makes plasma concentration monitoring difficult to standardize and contributes to variability in response across patients at the same nominal dose.8 Agomelatine is rapidly absorbed, with time to peak concentration (Tmax) of approximately one to two hours. It is extensively metabolized by CYP1A2 (primary) and CYP2C9 (secondary). Strong CYP1A2 inhibitors, including fluvoxamine and the fluoroquinolone antibiotic ciprofloxacin, markedly increase agomelatine exposure and are contraindicated with its use. Smoking induces CYP1A2 and substantially reduces agomelatine plasma concentrations, potentially reducing efficacy in heavy smokers. The drug should be administered at bedtime to align peak plasma concentration with the normal rise of endogenous melatonin and to maximize MT1/MT2 agonism during the relevant circadian window.
Agomelatine causes liver enzyme elevations in approximately 1% to 3% of patients, with rare cases of symptomatic hepatitis and hepatic failure reported post-marketing.8 The European Medicines Agency (EMA) prescribing guidelines require liver function testing at baseline, at 6 weeks, 12 weeks, and 24 weeks after initiation, and periodically thereafter. Agomelatine is contraindicated in patients with hepatic impairment. Any elevation of transaminases above three times the upper limit of normal requires discontinuation. This monitoring burden, combined with the low and variable bioavailability, distinguishes agomelatine's prescribing requirements from other oral antidepressants and must be incorporated into clinical follow-up planning from the time of initiation. Patients should not drink alcohol in significant amounts during agomelatine therapy, as alcohol potentiates hepatotoxic risk.
Agomelatine has demonstrated efficacy comparable to SSRIs and SNRIs in randomized controlled trials for MDD, with pooled effect sizes in the moderate range.9 A key clinical differentiator is its effect on sleep: agomelatine consistently improves subjective sleep quality, reduces sleep latency, and normalizes sleep architecture without producing next-day sedation, in contrast to the REM-suppressing effects of SSRIs and SNRIs. In patients with MDD for whom disrupted sleep is a primary complaint, and particularly in those with circadian phase misalignment, delayed sleep phase, or significant hypersomnia, agomelatine's mechanism offers a theoretically targeted approach. Agomelatine does not produce sexual dysfunction, weight gain, or SSRI-class gastrointestinal adverse effects, and it does not cause discontinuation syndrome upon abrupt cessation, which is consistent with its lack of effect on monoamine transporters.
Mandatory liver function monitoring at 6, 12, and 24 weeks. Contraindicated with fluvoxamine and ciprofloxacin (CYP1A2 inhibitors). Bedtime administration required. Contraindicated in hepatic impairment. Not FDA-approved; encountered in patients transferring care from European or Australian healthcare settings.
The five agents reviewed in this module occupy distinct clinical niches defined by their receptor profiles, adverse effect patterns, pharmacokinetic constraints, and the specific features of a patient's depressive presentation. None is a universal first-line agent, but each offers advantages in specific clinical contexts where standard SSRIs or SNRIs are inadequate or poorly tolerated.
Vortioxetine is the most appropriate choice among this module's agents when cognitive dysfunction is a dominant feature of the depressive presentation. Patients who report difficulty concentrating, slowed processing speed, impaired working memory, or poor executive function, and in whom these cognitive features persist despite adequate mood improvement on a prior antidepressant, are the population most likely to benefit from vortioxetine's pro-cognitive mechanism. It is also a reasonable alternative in patients who experienced sexual dysfunction on an SSRI or SNRI that was otherwise effective, given its more favorable sexual side effect profile. CYP2D6 genotyping, when available, should inform dosing: poor metabolizers should be capped at 10 mg daily.11 In patients without access to pharmacogenomic testing, awareness of CYP2D6 inhibitor coadministration is the key prescribing consideration, since agents such as bupropion, fluoxetine, and paroxetine substantially increase vortioxetine exposure.
Vilazodone occupies a narrow clinical niche relative to vortioxetine and SSRIs. Its strongest mechanistic rationale is in patients with comorbid MDD and generalized anxiety disorder (GAD), where its 5-HT1A partial agonism may produce anxiolytic effects complementary to its antidepressant activity, analogous to the mechanism of buspirone in GAD but with concurrent SERT inhibition. For patients who have not responded to an SSRI alone and whose residual symptoms include prominent anxiety, a trial of vilazodone provides a mechanistically distinct option without switching to an SNRI. The mandatory food coadministration requires explicit patient education at the time of prescribing, and the dose titration schedule must be followed to minimize early gastrointestinal adverse effects that are a common driver of premature discontinuation.
Trazodone's primary clinical role in contemporary practice is as a non-scheduled hypnotic for insomnia comorbid with MDD or occurring in patients for whom benzodiazepines and z-drugs are contraindicated or poorly tolerated. At doses of 50 mg to 150 mg at bedtime, trazodone improves sleep onset latency and sleep continuity without producing next-day impairment at these doses in most patients.5 It is commonly combined with SSRIs or SNRIs as augmentation for insomnia rather than used as a stand-alone antidepressant. The priapism risk, though rare, requires explicit informed consent in male patients at initiation. Trazodone is also used as an augmenting agent in patients with MDD who have achieved partial antidepressant response with an SSRI but who continue to have significant sleep disruption as a residual symptom.
Given nefazodone's hepatotoxicity risk and broad CYP3A4 inhibitory interactions, it should not be considered for patients who have not exhausted safer alternatives. The only clinical scenario where nefazodone retains a reasonable risk-benefit profile is in patients with truly refractory depression, typically defined as failure of two or more adequate antidepressant trials at therapeutic doses for adequate duration, who require an antidepressant with REM sleep preservation and who cannot tolerate or have not responded to mirtazapine, TCAs, or MAOIs. Even in this scenario, baseline liver function testing, exclusion of hepatic disease, and informed consent regarding the hepatotoxicity risk are mandatory before initiation.6
Agomelatine is most rationally deployed in patients with MDD characterized by prominent sleep-wake cycle disruption, particularly delayed sleep phase, hypersomnia, or prominent diurnal variation in mood, where its circadian resynchronization mechanism directly targets a pathophysiological feature of the presentation rather than addressing sleep secondarily. In healthcare systems where agomelatine is available, it may also be preferred in patients for whom sexual side effects or discontinuation syndrome are key concerns, since it produces neither.9 In systems where it is unavailable, including routine US prescribing, the clinical niche it would occupy in sleep-disrupted MDD is typically addressed by low-dose trazodone augmentation or by the addition of melatonin to a standard antidepressant regimen, neither of which replicates agomelatine's combined MT1/MT2 plus 5-HT2C mechanism but which address the sleep component through overlapping pathways.
Vortioxetine: multimodal serotonergic with pro-cognitive and favorable sexual dysfunction profile. Vilazodone: SERT plus 5-HT1A partial agonism; food required; gastrointestinal adverse effects prominent; niche in comorbid anxiety. Trazodone: SARI predominantly used as non-scheduled hypnotic; priapism risk in males. Nefazodone: SARI with black box hepatotoxicity; CYP3A4 inhibitor; now rarely prescribed. Agomelatine: MT1/MT2 agonism plus 5-HT2C antagonism; no transporter activity; mandatory liver monitoring; not FDA-approved; niche in circadian-disrupted presentations.10
Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206–3221.
doi:10.1021/jm101459gMørk A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340(3):666–675.
doi:10.1124/jpet.111.189068McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557–1567.
doi:10.1017/S1461145714000546Stahl SM. Vilazodone, a multifunctional serotonin agent for the treatment of major depressive disorder. CNS Spectr. 2009;14(10):562–568.
doi:10.1017/S1092852900023889Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033–1049.
doi:10.1007/s40263-012-0010-5Choi S. Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ. 2003;169(11):1187.
doi:10.1503/cmaj.1031117Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954–964.
doi:10.1124/jpet.103.051797European Medicines Agency. Valdoxan (agomelatine): summary of product characteristics. EMA/CHMP/478555/2008. Amsterdam: EMA; 2009. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/valdoxan
Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71(2):109–120.
doi:10.4088/JCP.09m05347bluStahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021. Chapter 7.
US Food and Drug Administration. Trintellix (vortioxetine) prescribing information. Revised 2023. Silver Spring, MD: FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204447s020lbl.pdf
US Food and Drug Administration. Serzone (nefazodone hydrochloride) prescribing information. Silver Spring, MD: FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20152s020lbl.pdf